Recent advances in drug treatments for dry eye disease

References

• Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334–365. doi: 10.1016/j.jtos.2017.05.003
   PubMed Web of Science ®Google Scholar
• Alves M, Fonseca EC, Alves MF, et al. Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies. Ocul Surf. 2013;11(3):181–192. doi: 10.1016/j.jtos.2013.02.002
   PubMed Web of Science ®Google Scholar
• Mohamed HB, Abd El-Hamid BN, Fathalla D, et al. Current trends in pharmaceutical treatment of dry eye disease: a review. Eur J Pharmaceut Sci. 2022;175:106206. doi: 10.1016/j.ejps.2022.106206
   PubMed Web of Science ®Google Scholar
• Sheppard J, Shen Lee B, Periman LM. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Ann Med. 2023;55(1):241–252. doi: 10.1080/07853890.2022.2157477
   PubMed Web of Science ®Google Scholar
• Bron AJ, Tiffany JM, Yokoi N, et al. Using osmolarity to diagnose dry eye: a compartmental hypothesis and review of our assumptions. Adv Exp Med Biol. 2002;506:B:1087–1095.
   Web of Science ®Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438–510. doi: 10.1016/j.jtos.2017.05.011
   PubMed Web of Science ®Google Scholar
• Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol. 2013;32(1):19–41. doi: 10.3109/08830185.2012.748052
   PubMed Web of Science ®Google Scholar
• Gipson IK, Argüeso P. Role of mucins in the function of the corneal and conjunctival epithelia. Int Rev Cytol. 2003;231:1–49.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Amescua G, Farid M, et al. Dry eye syndrome preferred practice pattern®. Ophthalmol. 2019;126:286–P334. doi: 10.1016/j.ophtha.2018.10.023
   PubMed Web of Science ®Google Scholar
• Chan TCY, Chow SSW, Wan KHN, et al. Update on the association between dry eye disease and meibomian gland dysfunction. Hong Kong Med J. 2019;25:38–47. doi: 10.12809/hkmj187331
   PubMed Web of Science ®Google Scholar
• Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye Contact Lens. 2014;40(4):248. doi: 10.1097/ICL.0000000000000042
   PubMed Web of Science ®Google Scholar
• Tsubota K, Pflugfelder SC, Liu Z, et al. Defining dry eye from a clinical perspective. Int J Mol Sci. 2020;21(23):1–24. doi: 10.3390/ijms21239271
   Web of Science ®Google Scholar
• Buckley RJ. Assessment and management of dry eye disease. Eye. 2018;32(2):200. doi: 10.1038/eye.2017.289
   PubMed Web of Science ®Google Scholar
• Dogru M, Nakamura M, Shimazaki J, et al. Changing trends in the treatment of dry-eye disease. Expert Opin Investig Drugs. 2013;22(12):1581–1601. doi: 10.1517/13543784.2013.838557
   PubMed Web of Science ®Google Scholar
• Marshall LL, Roach JM. Treatment of dry eye disease. Consult Pharm. 2016;31(2):96–106. doi: 10.4140/TCP.n.2016.96
   PubMedGoogle Scholar
• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–283. doi: 10.1016/j.jtos.2017.05.008
   PubMed Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575–628. doi: 10.1016/j.jtos.2017.05.006
   PubMed Web of Science ®Google Scholar
• Clayton JA, Longo DL. Dry eye. N Engl J Med. 2018;378:2212–2223. doi: 10.1056/NEJMra1407936
   PubMed Web of Science ®Google Scholar
• Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006;7:675–678. doi: 10.1631/jzus.2006.B0675
   PubMedGoogle Scholar
• Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017 Feb 28;2017(2). Epub ahead of print. doi: 10.1002/14651858.CD009327.PUB3
   Google Scholar
• Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:336.
   PubMedGoogle Scholar
• Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmol. 2017;124(1):53–60. doi: 10.1016/j.ophtha.2016.09.025
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. Cornea. 2016;35(6):741–748. doi: 10.1097/ICO.0000000000000803
   PubMed Web of Science ®Google Scholar
• Holland E, Nichols K, Foulks G, et al. Efficacy and safety of KPI-121 0.25% for short term relief in dry eye (STRIDE). American Society of Cataract and Refractive Surgery Virtual Annual Meeting; 2020 May 16-17; Virtual Meeting.
   Google Scholar
• Wirta DL, Torkildsen GL, Moreira HR, et al. A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease. Ophthalmology. 2019;126(6):792–800. doi: 10.1016/j.ophtha.2019.01.024
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Wirta DL, McLaurin E, et al. A water-free 0.1% cyclosporine a solution for treatment of dry eye disease: results of the randomized phase 2B/3 ESSENCE study. Cornea. 2021;40(10):1290–1297. doi: 10.1097/ICO.0000000000002633
   PubMed Web of Science ®Google Scholar
• Wirta D, Torkildsen GL, Boehmer B, et al. ONSET-1 phase 2b randomized trial to evaluate the safety and efficacy of OC-01 (Varenicline solution) nasal spray on signs and symptoms of dry eye disease. Cornea. 2022;41(10):1207–1216. doi: 10.1097/ICO.0000000000002941
   PubMed Web of Science ®Google Scholar
• Wirta D, Vollmer P, Paauw J, et al. Efficacy and safety of OC-01 (Varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial. Ophthalmology. 2022;129(4):379–387. doi: 10.1016/j.ophtha.2021.11.004
   PubMed Web of Science ®Google Scholar
• Quiroz-Mercado H, Hernandez-Quintela E, Chiu KH, et al. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: the MYSTIC study. Ocul Surf. 2022;24:15–21. doi: 10.1016/j.jtos.2021.12.007
   PubMed Web of Science ®Google Scholar
• Peng W, Chen RX, Dai H, et al. Efficacy, safety, and tolerability of a novel cyclosporine, a formulation for dry eye disease: a multicenter phase II clinical study. Clin Ther. 2021;43:613–628. doi: 10.1016/j.clinthera.2020.12.023
   PubMed Web of Science ®Google Scholar
• Peng W, Jiang X, Zhu L, et al. Cyclosporine a (0.05%) ophthalmic gel in the treatment of dry eye disease: a multicenter, randomized, double-masked, phase III, COSMO trial. Drug Des Devel Ther. 2022;16:3183–3194. doi: 10.2147/DDDT.S370559
   PubMed Web of Science ®Google Scholar
• Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287–296. doi: 10.5301/ejo.5000779
   PubMed Web of Science ®Google Scholar
• Baudouin C, De La Maza MS, Amrane M, et al. One-year efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27(6):678–685. doi: 10.5301/ejo.5001002
   PubMed Web of Science ®Google Scholar
• Dong Y, Wang S, Cong L, et al. TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China. Int Ophthalmol. 2022;42(8):2459. doi: 10.1007/s10792-022-02245-1
   PubMed Web of Science ®Google Scholar
• Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491–496. doi: 10.1097/ICO.0000000000000379
   PubMed Web of Science ®Google Scholar
• Clark D, Sheppard J, Brady TC. A randomized double-masked phase 2a trial to evaluate activity and safety of topical ocular reproxalap, a novel RASP inhibitor, in dry eye disease. J Ocul Pharmacol Ther. 2021;37(4):193–199. doi: 10.1089/jop.2020.0087
   PubMed Web of Science ®Google Scholar
• Clark D, Tauber J, Sheppard J, et al. Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease. Am J Ophthalmol. 2021;226:22–31. doi: 10.1016/j.ajo.2021.01.011
   PubMed Web of Science ®Google Scholar
• Taylor M, Ousler G, Torkildsen G, et al. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease. Clin Ophthalmol. 2019;13:261–275. doi: 10.2147/OPTH.S189039
   PubMed Web of Science ®Google Scholar
• Sall K, Foulks G, Pflugfelder SC, et al. A phase 1/2a study of ALY688 ophthalmic solution in dry eye subjects. Invest Ophthalmol Vis Sci. 2023;64:3959–3959.
   Web of Science ®Google Scholar
• Takamura E, Tsubota K, Watanabe H, et al. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96(10):1310–1315. doi: 10.1136/bjophthalmol-2011-301448
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmol. 2012;119(12):2471–2478. doi: 10.1016/j.ophtha.2012.06.052
   PubMed Web of Science ®Google Scholar
• Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275. doi: 10.2147/OPTH.S44688
   PubMedGoogle Scholar
• Petrov A, Perekhvatova N, Skulachev M, et al. SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model. Adv Ther. 2016;33(1):96–115. doi: 10.1007/s12325-015-0274-5
   PubMed Web of Science ®Google Scholar
• Wirta DL, Senchyna M, Lewis AE, et al. A randomized, vehicle-controlled, phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1). Ocul Surf. 2022;26:166–173. doi: 10.1016/j.jtos.2022.08.003
   PubMed Web of Science ®Google Scholar
• Benitez-Del-Castillo JM, Moreno-Montañés J, Jiménez-Alfaro I, et al. Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease. Invest Ophthalmol Vis Sci. 2016;57(14):6447–6454. doi: 10.1167/iovs.16-20303
   PubMed Web of Science ®Google Scholar
• Celebi ARC, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study. Graefes Arch Clin Exp Ophthalmol. 2014;252(4):619–626. doi: 10.1007/s00417-014-2599-1
   PubMed Web of Science ®Google Scholar
• Avila MY, Igua AM, Mora AM. Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye. Br J Ophthalmol. 2018;103:648–653. doi: 10.1136/bjophthalmol-2018-312072
   Web of Science ®Google Scholar
• Pérez ML, Barreales S, Sabater-Cruz N, et al. Amniotic membrane extract eye drops: a new approach to severe ocular surface pathologies. Cell Tissue Bank. 2022;23(3):473–481. doi: 10.1007/s10561-021-09962-4
   PubMed Web of Science ®Google Scholar
• Arita R, Fukuoka S. Efficacy of azithromycin eyedrops for individuals with meibomian gland dysfunction-associated posterior blepharitis. Eye Contact Lens. 2021;47:54–59. doi: 10.1097/ICL.0000000000000729
   PubMed Web of Science ®Google Scholar
• Satitpitakul V, Ratanawongphaibul K, Kasetsuwan N, et al. Efficacy of azithromycin 1.5% eyedrops vs oral doxycycline in meibomian gland dysfunction: a randomized trial. Graefes Arch Clin Exp Ophthalmol. 2019;257(6):1289–1294. doi: 10.1007/s00417-019-04322-1
   PubMed Web of Science ®Google Scholar
• Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol. 2005;19(4):258–263. doi: 10.3341/kjo.2005.19.4.258
   PubMedGoogle Scholar
• Lollett IV, Galor A. Dry eye syndrome: developments and lifitegrast in perspective. Clin Ophthalmol. 2018;12:125–139. doi: 10.2147/OPTH.S126668
   PubMed Web of Science ®Google Scholar
• Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153(6):1050–1060.e1. doi: 10.1016/j.ajo.2011.11.003
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475–483. doi: 10.1016/j.ophtha.2013.09.015
   PubMed Web of Science ®Google Scholar
• Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015;122:2423–2431. doi: 10.1016/j.ophtha.2015.08.001
   PubMed Web of Science ®Google Scholar
• Bodor N, Loftsson T, Wu W. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res. 1992;9:1275–1278. doi: 10.1023/A:1015849132396
   PubMed Web of Science ®Google Scholar
• Popov A. Mucus-penetrating particles and the role of ocular mucus as a barrier to micro- and Nanosuspensions. J Ocul Pharmacol Ther. 2020;36(6):366–375. doi: 10.1089/jop.2020.0022
   PubMed Web of Science ®Google Scholar
• Gupta PK, Venkateswaran N. The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares. Ther Adv Ophthalmol. 2021;13:251584142110127. doi: 10.1177/25158414211012797
   Google Scholar
• Efficacy and safety of KPI-121 0.25% for short term relief in dry eye (STRIDE). [cited 2023 Aug 23]. Available from: https://ascrs.confex.com/ascrs/20am/meetingapp.cgi/Paper/71273
   Google Scholar
• Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444–457. doi: 10.1016/j.ajo.2004.04.052
   PubMed Web of Science ®Google Scholar
• Barabino S, Montaldo E, Corsi E, et al. The effect of tapered small dose steroidal treatment on symptoms, clinical signs, and ocular surface inflammation in patients with dry eye syndrome. Invest Ophthalmol Vis Sci. 2011;52:3826–3826.
   Google Scholar
• Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis. 2014;6:OED.S16067. doi: 10.4137/OED.S16067
   PubMedGoogle Scholar
• Kymionis GD, Bouzoukis DI, Diakonis VF, et al. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol. 2008;2:829. doi: 10.2147/OPTH.S1409
   PubMedGoogle Scholar
• Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126:1046–1050. doi: 10.1001/archopht.126.8.1046
   PubMedGoogle Scholar
• de Paiva CS, Pflugfelder SC, Ng SM, et al. Topical cyclosporine a therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019 Sep 13;9. Epub ahead of print. doi: 10.1002/14651858.CD010051.PUB2
   PubMedGoogle Scholar
• Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine a in dry eye disease and recent formulation developments. Clin Ophthalmol. 2020;14:4187–4200. doi: 10.2147/OPTH.S279051
   PubMed Web of Science ®Google Scholar
• Lallemand F, Felt-Baeyens O, Besseghir K, et al. Cyclosporine a delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56(3):307–318. doi: 10.1016/S0939-6411(03)00138-3
   PubMed Web of Science ®Google Scholar
• Sheppard J, Kannarr S, Luchs J, et al. Efficacy and safety of OTX-101, a novel nanomicellar formulation of cyclosporine A, for the treatment of Keratoconjunctivitis Sicca: pooled analysis of a phase 2b/3 and phase 3 study. Eye Contact Lens. 2020;46(Suppl 1):S14–S19. doi: 10.1097/ICL.0000000000000636
   PubMed Web of Science ®Google Scholar
• Dutescu RM, Panfil C, Merkel OM, et al. Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery. Eur J Pharm Biopharm. 2014;88(1):123–128. doi: 10.1016/j.ejpb.2014.05.009
   PubMed Web of Science ®Google Scholar
• Agarwal P, Scherer D, Günther B, et al. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. Int J Pharm. 2018;538(1–2):119–129. doi: 10.1016/j.ijpharm.2018.01.019
   PubMedGoogle Scholar
• Zitko KL, Ladd L, Dougherty TS. Intranasal varenicline: review of a novel formulation for the treatment of dry eye disease. J Pharm Pract. 2022. Epub ahead of print. doi: 10.1177/08971900221108725.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Varenicline solution nasal spray: a review in dry eye disease. Drugs. 2022;82(14):1481–1488. doi: 10.1007/s40265-022-01782-4
   PubMed Web of Science ®Google Scholar
• Tauber J, Wirta DL, Sall K, et al. A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease. Cornea. 2021;40(9):1132–1140. doi: 10.1097/ICO.0000000000002622
   PubMed Web of Science ®Google Scholar
• Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology. 2023 May;130(5):516–524. Epub ahead of print. doi: 10.1016/J.OPHTHA.2022.12.021
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Kurata F, Epitropoulos AT, et al. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol. 2023 Mar 20;252. Epub ahead of print. doi: 10.1016/J.AJO.2023.03.008.
   PubMed Web of Science ®Google Scholar
• Daull P, Lallemand F, Philips B, et al. Distribution of cyclosporine a in ocular tissues after topical administration of cyclosporine a cationic emulsions to pigmented rabbits. Cornea. 2013;32(3):345–354. doi: 10.1097/ICO.0b013e31825e83f4
   PubMed Web of Science ®Google Scholar
• Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21(1):15–34. doi: 10.1016/S1350-9462(01)00017-9
   PubMed Web of Science ®Google Scholar
• Lallemand F, Daull P, Benita S, et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012;2012:1–16. doi: 10.1155/2012/604204
   Google Scholar
• Ikervis | European medicines agency. [cited 2023 Jul 3]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis
   Google Scholar
• Baudouin C, Figueiredo FC, Messmer EM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine a cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27(5):520–530. doi: 10.5301/ejo.5000952
   PubMed Web of Science ®Google Scholar
• Bremond-Gignac D, Doan S, Amrane M, et al. Twelve-month results of cyclosporine a cationic emulsion in a randomized study in patients with pediatric vernal keratoconjunctivitis. Am J Ophthalmol. 2020;212:116–126. doi: 10.1016/j.ajo.2019.11.020
   PubMed Web of Science ®Google Scholar
• Leonardi A, Doan S, Amrane M, et al. A randomized, controlled trial of cyclosporine a cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study. Ophthalmol. 2019;126(5):671–681. doi: 10.1016/j.ophtha.2018.12.027
   PubMed Web of Science ®Google Scholar
• Sheha H, Tighe S, Hashem O, et al. Update on Cenegermin eye drops in the treatment of neurotrophic keratitis. Clin Ophthalmol. 2019;13:1973–1980. doi: 10.2147/OPTH.S185184
   PubMed Web of Science ®Google Scholar
• Aloe L, Rocco M, Balzamino B, et al. Nerve growth factor: a focus on neuroscience and therapy. Curr Neuropharmacol. 2015;13(3):294–303. doi: 10.2174/1570159X13666150403231920
   PubMed Web of Science ®Google Scholar
• Lambiase A, Rama P, Bonini S, et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998;338:372–373. doi: 10.1056/NEJM199804233381702
   PubMed Web of Science ®Google Scholar
• Lambiase A, Sacchetti M, Bonini S. Nerve growth factor therapy for corneal disease. Curr Opin Ophthalmol. 2012;23(4):296–302. doi: 10.1097/ICU.0b013e3283543b61
   PubMed Web of Science ®Google Scholar
• Coco G, Piccotti G, Romano V, et al. Cenegermin for the treatment of dry eye disease. Drugs Today (Barc). 2023;59:113–123.
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Lambiase A, Schmidl D, et al. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. Br J Ophthalmol. 2020;104:127–135. doi: 10.1136/bjophthalmol-2018-312470
   PubMed Web of Science ®Google Scholar
• Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev. 2014;25:453–472. doi: 10.1016/j.cytogfr.2014.07.016
   PubMed Web of Science ®Google Scholar
• Lee HB, Choi HJ, Cho SM, et al. Efficacy of HL036 versus cyclosporine a in the treatment of naturally occurring canine keratoconjunctivitis sicca. Curr Eye Res. 2018;43(7):889–895. doi: 10.1080/02713683.2018.1461909
   PubMed Web of Science ®Google Scholar
• Sosne G, Xu L, Prach L, et al. Thymosin beta 4 stimulates laminin-5 production independent of TGF-beta. Exp Cell Res. 2004;293(1):175–183. doi: 10.1016/j.yexcr.2003.09.022
   PubMed Web of Science ®Google Scholar
• Sosne G, Qiu P, Christopherson PL, et al. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84:663–669. doi: 10.1016/j.exer.2006.12.004
   PubMed Web of Science ®Google Scholar
• Sosne G, Hafeez S, Greenberry AL, et al. Thymosin beta4 promotes human conjunctival epithelial cell migration. Curr Eye Res. 2002;24:268–273. doi: 10.1076/ceyr.24.4.268.8414
   PubMed Web of Science ®Google Scholar
• Dunn SP, Heidemann DG, Chow CYC, et al. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. Ann N Y Acad Sci. 2010;1194:199–206. doi: 10.1111/j.1749-6632.2010.05471.x
   PubMed Web of Science ®Google Scholar
• Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment (CAETM) model. Clin Ophthalmol. 2015;9:877–884. doi: 10.2147/OPTH.S80954
   PubMed Web of Science ®Google Scholar
• Zhai Y, Zheng X, Mao Y, et al. Recombinant human thymosin β4 (rhTβ4) modulates the anti-inflammatory responses to alleviate benzalkonium chloride (BAC)-induced dry eye disease. IJMS. 2022 May 1;23(10):5458. Epub ahead of print. doi: 10.3390/IJMS23105458
   Google Scholar
• Kovalchin J, King B, Masci A, et al. Preclinical development of EBI-005: an IL-1 receptor-1 inhibitor for the topical ocular treatment of ocular surface inflammatory diseases. Eye Contact Lens. 2018;44:170–181. doi: 10.1097/ICL.0000000000000414
   PubMed Web of Science ®Google Scholar
• Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283–2292.
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Martel JR, Sall K, et al. Multicenter study of a novel topical interleukin-1 receptor inhibitor, Isunakinra, in subjects with moderate to severe dry eye disease. Eye Contact Lens. 2017;43:287–296. doi: 10.1097/ICL.0000000000000276
   PubMed Web of Science ®Google Scholar
• Higdon A, Diers AR, Oh JY, et al. Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem J. 2012;442(3):453. doi: 10.1042/BJ20111752
   PubMed Web of Science ®Google Scholar
• Kalariya NM, Ramana KV, Srivastava SK, et al. Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells. Exp Eye Res. 2008;86:70–80. doi: 10.1016/j.exer.2007.09.010
   PubMed Web of Science ®Google Scholar
• Kauppinen A, Niskanen H, Suuronen T, et al. Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells–implications for age-related macular degeneration (AMD). Immunol Lett. 2012;147:29–33. doi: 10.1016/j.imlet.2012.05.005
   PubMed Web of Science ®Google Scholar
• Sapkota M, DeVasure JM, Kharbanda KK, et al. Malondialdehyde-acetaldehyde (MAA) adducted surfactant protein induced lung inflammation is mediated through scavenger receptor a (SR-A1). Respir Res. 2017 Feb 13;18. Epub ahead of print. doi: 10.1186/S12931-017-0517-X
   PubMed Web of Science ®Google Scholar
• Sandikci R, Türkmen S, Güvenen G, et al. Lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet’s disease. Acta Derm Venereol. 2003;83(5):342–346. doi: 10.1080/00015550310003782
   PubMed Web of Science ®Google Scholar
• Čejkova J, Ardan T, Jirsová K, et al. The role of conjunctival epithelial cell xanthine oxidoreductase/xanthine oxidase in oxidative reactions on the ocular surface of dry eye patients with Sjögren’s syndrome. Histol Histopathol. 2007;22:997–1003. doi: 10.14670/HH-22.997
   PubMed Web of Science ®Google Scholar
• Balci M, Şahin Ş, Mutlu FM, et al. Investigation of oxidative stress in pterygium tissue. Mol Vis. 2011;17:443.
   PubMed Web of Science ®Google Scholar
• Turk A, Aykut M, Akyol N, et al. Serum anti-carbonic anhydrase antibodies and oxidant-antioxidant balance in patients with acute anterior uveitis. Ocul Immunol Inflamm. 2014;22:127–132. doi: 10.3109/09273948.2013.830753
   PubMed Web of Science ®Google Scholar
• Hagan S, Fyfe MCT, Ofori-Frimpong B, et al. Narrow spectrum kinase inhibitors demonstrate promise for the treatment of dry eye disease and other ocular inflammatory disorders. Invest Ophthalmol Vis Sci. 2018;59(3):1443–1453. doi: 10.1167/iovs.17-23479
   PubMed Web of Science ®Google Scholar
• Koh S, Maeda N, Ikeda C, et al. Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye. Acta Ophthalmol. 2014;92:e671–e675. doi: 10.1111/aos.12443
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Ohashi Y, Watanabe H, et al. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmol. 2012;119(10):1954–1960. doi: 10.1016/j.ophtha.2012.04.010
   PubMed Web of Science ®Google Scholar
• Gong L, Sun X, Ma Z, et al. A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore. Br J Ophthalmol. 2015;99(7):903–908. doi: 10.1136/bjophthalmol-2014-306084
   PubMed Web of Science ®Google Scholar
• Liu S, Yang G, Li Q, et al. Safety and efficacy of topical diquafosol for the treatment of dry eye disease: an updated meta-analysis of randomized controlled trials. Indian J Ophthalmol. 2023;71(4):1304–1315. doi: 10.4103/IJO.IJO_268_23
   PubMed Web of Science ®Google Scholar
• Sun X, Liu L, Liu C. Topical diquafosol versus hyaluronic acid for the treatment of dry eye disease: a meta-analysis of randomized controlled trials. Graefes Arch Clin Exp Ophthalmol. 2023. Epub ahead of print. doi: 10.1007/S00417-023-06083-4
   Web of Science ®Google Scholar
• Kinoshita S, Oshiden K, Awamura S, et al. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology. 2013;120(6):1158–1165. doi: 10.1016/j.ophtha.2012.12.022
   PubMed Web of Science ®Google Scholar
• Munakata W, Liu Q, Shimoyama T, et al. Ecabet sodium attenuates reactive oxygen species produced by neutrophils after priming with bacterial lipopolysaccharides. Luminescence. 2003;18(6):330–333. doi: 10.1002/bio.745
   PubMed Web of Science ®Google Scholar
• Mito C, Tokushige H, Kida T, et al. Ecabet sodium promotes MUC5AC secretion in rabbit tears. Invest Ophthalmol Vis Sci. 2007;48:384–384.
   Google Scholar
• Skulachev VP. Cationic antioxidants as a powerful tool against mitochondrial oxidative stress. Biochem Biophys Res Commun. 2013;441(2):275–279. doi: 10.1016/j.bbrc.2013.10.063
   PubMed Web of Science ®Google Scholar
• Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15:404–437. doi: 10.1016/j.jtos.2017.05.002
   PubMed Web of Science ®Google Scholar
• Lu PY, Xie F, Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet. 2005;54:115–142.
   Web of Science ®Google Scholar
• Pan Z, Wang Z, Yang H, et al. TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2011;52(1):485. doi: 10.1167/iovs.10-5801
   PubMed Web of Science ®Google Scholar
• Pan Z. Transient receptor potential (TRP) channels in the eye. Adv Ophthalmol. 2012 Mar 7. Epub ahead of print. doi: 10.5772/34598
   Google Scholar
• Shtein RM, Shen JF, Kuo AN, et al. Autologous serum-based eye drops for treatment of ocular surface disease: a report by the American Academy of Ophthalmology. Ophthalmology. 2020;127(1):128–133. doi: 10.1016/j.ophtha.2019.08.018
   PubMed Web of Science ®Google Scholar
• Tsubota K, Goto E, Shimmura S, et al. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106(10):1984–1989. doi: 10.1016/S0161-6420(99)90412-8
   PubMed Web of Science ®Google Scholar
• Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjögren’s syndrome. Br J Ophthalmol. 1999;83:390–395. doi: 10.1136/bjo.83.4.390
   PubMed Web of Science ®Google Scholar
• Geerling G, MacLennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004;88:1467–1474. doi: 10.1136/bjo.2004.044347
   PubMed Web of Science ®Google Scholar
• Ralph RA, Doane MG, Dohlman CH. Clinical experience with a mobile ocular perfusion pump. Arch Ophthalmol. 1975;93(10):1039–1043. doi: 10.1001/archopht.1975.01010020815015
   PubMedGoogle Scholar
• Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017 Feb 28;2017. Epub ahead of print. doi: 10.1002/14651858.CD009327.PUB3
   Google Scholar
• Kumari N, Kusumesh R, Kumari R, et al. Comparative evaluation of effectiveness of twenty versus fifty percent autologous serum eye drops in treatment of dry eye. Indian J Ophthalmol. 2023;71(4):1603–1607. doi: 10.4103/IJO.IJO_2684_22
   PubMed Web of Science ®Google Scholar
• Alio JL, Rodriguez AE, Ferreira-Oliveira R, et al. Treatment of dry eye disease with autologous Platelet-rich plasma: a prospective, interventional, non-randomized study. Ophthalmol Ther. 2017;6(2):285–293. doi: 10.1007/s40123-017-0100-z
   PubMed Web of Science ®Google Scholar
• Wei Y, Asbell PA. The core mechanism of dry eye disease (DED) is inflammation. Eye Contact Lens. 2014;40:248. doi: 10.1097/ICL.0000000000000042
   PubMed Web of Science ®Google Scholar
• Bourgeois M, Loisel F, Obert L, et al. Can the amniotic membrane be used to treat peripheral nerve defects? A review of literature. Hand Surg Rehabil. 2019;38:223–232. doi: 10.1016/j.hansur.2019.05.006
   PubMed Web of Science ®Google Scholar
• Jeng BH, Hamrah P, Kirshner ZZ, et al. Exploratory phase II multicenter, open-label, clinical trial of ST266, a novel secretome for treatment of persistent corneal epithelial defects. Trans Vis Sci Tech. 2022 Jan 1;11(1):8. Epub ahead of print. doi: 10.1167/TVST.11.1.8
   PubMed Web of Science ®Google Scholar
• Murri MS, Moshirfar M, Birdsong OC, et al. Amniotic membrane extract and eye drops: a review of literature and clinical application. Clin Ophthalmol. 2018;12:1105. doi: 10.2147/OPTH.S165553
   PubMed Web of Science ®Google Scholar
• Zhang L, Su Z, Zhang Z, et al. Effects of azithromycin on gene expression profiles of proinflammatory and anti-inflammatory mediators in the eyelid margin and conjunctiva of patients with meibomian gland disease. JAMA Ophthalmol. 2015;133(10):1117–1123. doi: 10.1001/jamaophthalmol.2015.2326
   PubMed Web of Science ®Google Scholar
• Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008;25(9):858–870. doi: 10.1007/s12325-008-0096-9
   PubMed Web of Science ®Google Scholar
• Kagkelaris KA, Makri OE, Georgakopoulos CD, et al. An eye for azithromycin: review of the literature. Ther Adv Ophthalmol. 2018;10:251584141878362. doi: 10.1177/2515841418783622
   Web of Science ®Google Scholar
• Liu Y, Kam WR, Ding J, et al. Can tetracycline antibiotics duplicate the ability of azithromycin to stimulate human meibomian gland epithelial cell differentiation? Cornea. 2015;34(3):342–346. doi: 10.1097/ICO.0000000000000351
   PubMed Web of Science ®Google Scholar
• Tao T, Tao L. Systematic review and meta-analysis of treating meibomian gland dysfunction with azithromycin. Eye. 2020;34:1797–1808. doi: 10.1038/s41433-020-0876-2
   PubMed Web of Science ®Google Scholar
• Upaphong P, Tangmonkongvoragul C, Phinyo P. Pulsed oral azithromycin vs 6-week oral doxycycline for moderate to severe meibomian gland dysfunction: a randomized clinical trial. JAMA Ophthalmol. 2023 Mar 23;141(5):423. Epub ahead of print. doi: 10.1001/JAMAOPHTHALMOL.2023.0302
   PubMed Web of Science ®Google Scholar
• Heim KC, Angers P, Léonhart S, et al. Anti-inflammatory and neuroactive properties of selected fruit extracts. J Med Food. 2012;15(9):851–854. doi: 10.1089/jmf.2011.0265
   PubMed Web of Science ®Google Scholar
• Remsberg CM, Yáñez JA, Ohgami Y, et al. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother Res. 2008;22(2):169–179. doi: 10.1002/ptr.2277
   PubMed Web of Science ®Google Scholar
• Deng R, Hua X, Li J, et al. Oxidative stress markers induced by hyperosmolarity in primary human corneal epithelial cells. PLoS One. 2015;10(5):126561. doi: 10.1371/journal.pone.0126561
   PubMed Web of Science ®Google Scholar
• Wakamatsu TH, Dogru M, Matsumoto Y, et al. Evaluation of lipid oxidative stress status in sjögren syndrome patients. Invest Ophthalmol Vis Sci. 2013;54(1):201–210. doi: 10.1167/iovs.12-10325
   PubMed Web of Science ®Google Scholar
• Li J, Deng R, Hua X, et al. Blueberry component pterostilbene protects corneal epithelial cells from inflammation via anti-oxidative pathway. Sci Rep. 2016 Jan 14;6. Epub ahead of print. doi: 10.1038/SREP19408.
   Web of Science ®Google Scholar
• James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71(1):343S–348S. Epub ahead of print. doi: 10.1093/AJCN/71.1.343S
   PubMed Web of Science ®Google Scholar
• Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol. 2010;177(4):1576–1591. doi: 10.2353/ajpath.2010.100322
   PubMed Web of Science ®Google Scholar
• Hussain M, Shtein RM, Pistilli M, et al. The dry eye assessment and management (DREAM) extension study – a randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease. Ocul Surf. 2020;18(1):47. doi: 10.1016/j.jtos.2019.08.002
   PubMed Web of Science ®Google Scholar
• Giannaccare G, Pellegrini M, Sebastiani S, et al. Efficacy of omega-3 fatty acid supplementation for treatment of dry eye disease: a meta-analysis of randomized clinical trials. Cornea. 2019;38(5):565–573. doi: 10.1097/ICO.0000000000001884
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Senni C, Bernabei F, et al. The role of nutrition and nutritional supplements in ocular surface diseases. Nutrients. 2020 Apr 1;12(4):952. Epub ahead of print. doi: 10.3390/NU12040952
   PubMed Web of Science ®Google Scholar
• Nagai N, Otake H. Novel drug delivery systems for the management of dry eye. Adv Drug Deliv Rev. 2022 Dec 1;191. Epub ahead of print. doi: 10.1016/J.ADDR.2022.114582
   PubMed Web of Science ®Google Scholar
• Borgia A, Raimondi R, Fossati G, et al. Device-based therapies as a boost of conventional treatment in dry eye disease. Expert Rev Ophthalmol. 2022;17(6):387–393. doi: 10.1080/17469899.2022.2147928
   Web of Science ®Google Scholar